Prognostic value of PTEN in <i>de novo</i> diagnosed metastatic prostate cancer.

Jun-yu Zhang; Yun-yi Kong; Qi-feng Wang; Yun-jie Yang; Zheng Liu; Nan Lin; Ding-wei YE; Bo Dai

Return

Prognostic value of PTEN in de novo diagnosed metastatic prostate cancer.

Author: Jun-Yu ZHANG ¹ ; Yun-Yi KONG ² ; Qi-Feng WANG ² ; Yun-Jie YANG ¹ ; Zheng LIU ¹ ; Nan LIN ¹ ; Ding-Wei YE ¹ ; Bo DAI ¹
Author Information

1. Department of Urology, Fudan University Shanghai Cancer Center, Shanghai 200032, China.
2. Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai 200032, China.
Publication Type:Journal Article
Keywords: immunohistochemistry; metastatic prostate cancer; metastatic volume; phosphatase and tensin homolog on chromosome 10; prognosis
MeSH: China/epidemiology*; Humans; Male; PTEN Phosphohydrolase/genetics*; Prognosis; Prostatic Neoplasms; Retrospective Studies
From: Asian Journal of Andrology 2022;24(1):50-55
CountryChina
Language:English
Abstract: The purpose of our study is to investigate the prognostic value of phosphatase and tensin homolog on chromosome 10 (PTEN) expression in patients with de novo metastatic castration naïve prostate cancer (mCNPC). A total of 205 patients with mCNPC at Fudan University Shanghai Cancer Center (Shanghai, China) were retrospectively examined. Immunohistochemical staining of PTEN was performed on prostate biopsy samples of these patients. Associations among clinicopathological features, patient survival and PTEN protein expression were analyzed. PTEN loss occurred in 58 of 205 (28.3%) patients. Loss of PTEN was significantly correlated with high metastatic volume (P = 0.017). No association between PTEN expression and Gleason score was observed. Patients with PTEN loss had significantly shorter progression-free survival (PFS, P < 0.001) and overall survival (OS, P < 0.001) compared with patients with intact PTEN expression. Multivariate analysis showed that elevated alkaline phosphatase, high metastatic volume and PTEN loss were independent poor prognostic factors for PFS. The Eastern Cooperative Oncology Group performance status (ECOG PS)#8805; 2 and PTEN loss were independent poor prognostic factors for OS. The adjusted hazard ratio of PTEN loss for PFS and OS was 1.67 (95% confidence interval [CI]: 1.14-2.43, P = 0.008) and 1.95 (95% CI: 1.23-3.10, P = 0.005), respectively. PTEN loss was also significantly associated with shorter PFS (P = 0.025) and OS (P < 0.001) in patients with low-volume metastatic disease. Our data showed that PTEN loss is an independent predictor for shorter PFS and OS in patients with de novo mCNPC.